Mutant ROS expression in human cancer

US9364477B2 · kind B2 · utility

Assignee

• CELL SIGNALING TECHNOLOGY, INC. · US

Inventors

• Ting-Lei Gu · Woburn, US
• Meghan Ann Tucker · Salem, US
• Herbert Haack · Hamilton, US
• Katherine Eleanor Crosby · Middleton, US
• Victoria McGuinness Rimkunas · Somerville, US

Key dates

• Filing date: Feb 12, 2010
• Grant date: Jun 14, 2016
• Expiry date: Oct 1, 2030

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides the identification of the presence of mutant ROS protein in human cancer. In some embodiments, the mutant ROS are FIG-ROS fusion proteins comprising part of the FIG protein fused to the kinase domain of the ROS kinase. In some embodiments, the mutant ROS is the overexpression of wild-type ROS in cancerous tissues (or tissues suspected of being cancerous) where, in normal tissue of that same tissue type, ROS is not expressed or is expressed at lower levels. The mutant ROS proteins of the invention are anticipated to drive the proliferation and survival of a subgroup of human cancers, particularly in cancers of the liver (including bile duct), pancreas, kidney, and testes. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS polypeptides (e.g., a FIG-ROS(S) fusion polypeptide), probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The identification of the mutant ROS polypeptides enables new methods for determining the presence of these mutant ROS polypeptides in a biological sample, methods for screening for …